+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global T-Cell Immunotherapy Market (2023-2028) Competitive Analysis, Impact of Economic Slowdown & Impending Recession, Ansoff Analysis

  • PDF Icon

    Report

  • 183 Pages
  • February 2024
  • Region: Global
  • Infogence Global Research
  • ID: 5754608
The Global T-Cell Immunotherapy Market is estimated to be USD 5.54 Bn in 2023 and is expected to reach USD 10.14 Bn by 2028 growing at a CAGR of 12.86%.

Market Dynamics

Market dynamics are forces that impact the prices and behaviors of the stakeholders. These forces create pricing signals which result from the changes in the supply and demand curves for a given product or service. Forces of Market Dynamics may be related to macro-economic and micro-economic factors. There are dynamic market forces other than price, demand, and supply. Human emotions can also drive decisions, influence the market, and create price signals.

As the market dynamics impact the supply and demand curves, decision-makers aim to determine the best way to use various financial tools to stem various strategies for speeding the growth and reducing the risks.

Market Segmentations

  • The Global T-Cell Immunotherapy Market is segmented based on Therapy Type, Mechanism of Action, Product Class, Indication, Modality, and Geography.
  • By Therapy Type, the market is classified into CAR T-cell Therapy, Cell Receptor (TCR)-based, and Tumor Infiltrating Lymphocytes (TIL)-based.
  • By Mechanism of Action, the market is classified into Active Immunotherapy and Passive Immunotherapy.
  • By Product Class, the market is classified into Bispecific Antibodies, Cytokines, Monoclonal Antibodies, and Oncolytic Virus Therapy.
  • By Indication, the market is classified into Hematologic Malignancies, Solid Tumors, and Others.
  • By Modality, the market is classified into Research and Commercialized.
  • By Geography, the market is classified into Americas, Europe, Middle East & Africa, and Asia-Pacific.

Company Profiles

The report provides a detailed analysis of the competitors in the market. It covers the financial performance analysis for the publicly listed companies in the market. The report also offers detailed information on the companies' recent development and competitive scenario. Some of the companies covered in this report are Amgen, Inc., Autolus Therapeutics plc., Bellicum Pharmaceuticals, Inc., Bluebird bio, Inc., Bristol-Myer Squibb, CARsgen Therapeutics, Ltd., Celgene Corp., etc.

Countries Studied

  • America (Argentina, Brazil, Canada, Chile, Colombia, Mexico, Peru, United States, Rest of Americas)
  • Europe (Austria, Belgium, Denmark, Finland, France, Germany, Italy, Netherlands, Norway, Poland, Russia, Spain, Sweden, Switzerland, United Kingdom, Rest of Europe)
  • Middle East and Africa (Egypt, Israel, Qatar, Saudi Arabia, South Africa, United Arab Emirates, Rest of MEA)
  • Asia-Pacific (Australia, Bangladesh, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Sri Lanka, Thailand, Taiwan, Rest of Asia-Pacific)

Competitive Quadrant

The report includes Competitive Quadrant, a proprietary tool to analyze and evaluate the position of companies based on their Industry Position score and Market Performance score. The tool uses various factors for categorizing the players into four categories. Some of these factors considered for analysis are financial performance over the last 3 years, growth strategies, innovation score, new product launches, investments, growth in market share, etc.

Ansoff Analysis

  • The report presents a detailed Ansoff matrix analysis for the Global T-Cell Immunotherapy Market. Ansoff Matrix, also known as Product/Market Expansion Grid, is a strategic tool used to design strategies for the growth of the company. The matrix can be used to evaluate approaches in four strategies viz. Market Development, Market Penetration, Product Development and Diversification. The matrix is also used for risk analysis to understand the risk involved with each approach.
  • The publisher analyses the Global T-Cell Immunotherapy Market using the Ansoff Matrix to provide the best approaches a company can take to improve its market position.
  • Based on the SWOT analysis conducted on the industry and industry players, the publisher has devised suitable strategies for market growth.

Why buy this report?

  • The report offers a comprehensive evaluation of the Global T-Cell Immunotherapy Market. The report includes in-depth qualitative analysis, verifiable data from authentic sources, and projections about market size. The projections are calculated using proven research methodologies.
  • The report has been compiled through extensive primary and secondary research. The primary research is done through interviews, surveys, and observation of renowned personnel in the industry.
  • The report includes an in-depth Market analysis using Porter's 5 forces model, PESTLE Analysis, and the Ansoff Matrix. In addition, the impact of COVID-19 and the impact of economic slowdown & impending recession on the Market are also featured in the report.
  • The report also includes the regulatory scenario in the industry, which will help you make a well-informed decision. The report discusses major regulatory bodies and major rules and regulations imposed on this sector across various geographies.
  • The report also contains the competitive analysis using Positioning Quadrants, the Proprietary competitive positioning tool.

Report Highlights:

  • A complete analysis of the market, including parent industry
  • Important market dynamics and trends
  • Market segmentation
  • Historical, current, and projected size of the market based on value and volume
  • Market shares and strategies of key players
  • Recommendations to companies for strengthening their foothold in the market

Table of Contents

1 Report Description
1.1 Study Objectives
1.2 Market Definition
1.3 Currency
1.4 Years Considered
1.5 Language
1.6 Key Stakeholders
2 Research Methodology
2.1 Research Process
2.2 Data Collection and Validation
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Models
2.3 Market Size Estimation
2.3.1 Bottom-Up Approach
2.3.2 Top-Down Approach
2.4 Assumptions of the Study
2.5 Limitations of the Study
3 Executive Summary
3.1 Introduction
3.2 Market Size, Segmentations and Outlook
4 Market Dynamics
4.1 Drivers
4.1.1 Rising Approval of Kymriah and Yescarta
4.1.2 Increasing Developments in CAR T-Cell Therapy for Solid Tumors
4.1.3 Growing Technological Advancements in Manufacturing Process
4.1.4 Increasing Prevalence of Cancer and Autoimmune Diseases
4.1.5 Increasing Use of Cell-Based Targeted Therapies
4.2 Restraints
4.2.1 High Prices of Therapies
4.2.2 Limitations of CAR-T Therapy
4.3 Opportunities
4.3.1 Increasing Facility Expansion for Cell and Gene Therapies
4.3.2 Rising Global Financings in Gene and Cell Therapy Arena
4.3.3 Ongoing Developments in Viral & Non-Viral Vector Manufacturing Arena
4.3.4 Rising Investment in Adoptive T-Cell Transfer Approaches of Disease Treatment
4.4 Challenges
4.4.1 Emergence of New Approaches such as Second-Generation, Next-Generation CAR-T Immunotherapy
4.4.2 Neurologic Toxicities and Cytokine Release Syndrome
5 Market Analysis
5.1 Regulatory Scenario
5.2 Porter's Five Forces Analysis
5.3 PESTLE Analysis
5.4 SWOT Analysis
5.5 Impact of Covid-19
5.6 Impact of Economic Slowdown & Impending Recession
5.7 Ansoff Matrix Analysis
6 Global T-Cell Immunotherapy Market, By Therapy Type
6.1 Introduction
6.2 CAR T-cell Therapy
6.3 Cell Receptor (TCR)-based
6.4 Tumor Infiltrating Lymphocytes (TIL)-based
7 Global T-Cell Immunotherapy Market, By Mechanism of Action
7.1 Introduction
7.2 Active Immunotherapy
7.3 Passive Immunotherapy
8 Global T-Cell Immunotherapy Market, By Product Class
8.1 Introduction
8.2 Bispecific Antibodies
8.3 Cytokines
8.4 Monoclonal Antibodies
8.5 Oncolytic Virus Therapy
9 Global T-Cell Immunotherapy Market, By Indication
9.1 Introduction
9.2 Hematologic Malignancies
9.2.1 Lymphoma
9.2.2 Leukemia
9.2.3 Myeloma
9.3 Solid Tumors
9.3.1 Melanoma
9.3.2 Brain & Central Nervous System
9.3.3 Liver cancer
9.3.4 Others
9.4 Others
10 Global T-Cell Immunotherapy Market, By Modality
10.1 Introduction
10.2 Research
10.3 Commercialized
11 Americas' T-Cell Immunotherapy Market
11.1 Introduction
11.2 Argentina
11.3 Brazil
11.4 Canada
11.5 Chile
11.6 Colombia
11.7 Mexico
11.8 Peru
11.9 United States
11.10 Rest of Americas
12 Europe's T-Cell Immunotherapy Market
12.1 Introduction
12.2 Austria
12.3 Belgium
12.4 Denmark
12.5 Finland
12.6 France
12.7 Germany
12.8 Italy
12.9 Netherlands
12.10 Norway
12.11 Poland
12.12 Russia
12.13 Spain
12.14 Sweden
12.15 Switzerland
12.16 United Kingdom
12.17 Rest of Europe
13 Middle East and Africa's T-Cell Immunotherapy Market
13.1 Introduction
13.2 Egypt
13.3 Israel
13.4 Qatar
13.5 Saudi Arabia
13.6 South Africa
13.7 United Arab Emirates
13.8 Rest of MEA
14 APAC's T-Cell Immunotherapy Market
14.1 Introduction
14.2 Australia
14.3 Bangladesh
14.4 China
14.5 India
14.6 Indonesia
14.7 Japan
14.8 Malaysia
14.9 Philippines
14.10 Singapore
14.11 South Korea
14.12 Sri Lanka
14.13 Thailand
14.14 Taiwan
14.15 Rest of Asia-Pacific
15 Competitive Landscape
15.1 Competitive Quadrant
15.2 Market Share Analysis
15.3 Strategic Initiatives
15.3.1 M&A and Investments
15.3.2 Partnerships and Collaborations
15.3.3 Product Developments and Improvements
16 Company Profiles
16.1 Adaptimmune Therapeutics PLC
16.2 Amgen, Inc.
16.3 Atara Biotherapeutics, Inc.
16.4 Autolus Therapeutics PLC
16.5 Bluebird bio, Inc.
16.6 Bristol-Myers Squibb Company
16.7 CARsgen Therapeutics, Ltd.
16.8 Cellectis SA
16.9 Celyad Oncology SA
16.10 Chimera Bioengineering
16.11 Eureka Therapeutics, Inc.
16.12 Fate Therapeutics
16.13 Gilead Sciences, Inc.
16.14 Innovative Cellular Therapeutics
16.15 Iovance Biotherapeutics, Inc.
16.16 Janssen Pharmaceuticals, Inc.
16.17 Kite Pharma, Inc.
16.18 LAVA Therapeutics B.V.
16.19 Legend Biotech Corp.
16.20 Lyell Immunopharma
16.21 Neogene Therapeutics
16.22 Novartis Ag
16.23 Oxford Vacmedix
16.24 Pfizer, Inc.
17 Appendix
17.1 Questionnaire

Companies Mentioned

  • Adaptimmune Therapeutics PLC
  • Amgen, Inc.
  • Atara Biotherapeutics, Inc.
  • Autolus Therapeutics PLC
  • Bluebird bio, Inc.
  • Bristol-Myers Squibb Company
  • CARsgen Therapeutics, Ltd.
  • Cellectis SA
  • Celyad Oncology SA
  • Chimera Bioengineering
  • Eureka Therapeutics, Inc.
  • Fate Therapeutics
  • Gilead Sciences, Inc.
  • Innovative Cellular Therapeutics
  • Iovance Biotherapeutics, Inc.
  • Janssen Pharmaceuticals, Inc.
  • Kite Pharma, Inc.
  • LAVA Therapeutics B.V.
  • Legend Biotech Corp.
  • Lyell Immunopharma
  • Neogene Therapeutics
  • Novartis Ag
  • Oxford Vacmedix
  • Pfizer, Inc.

Table Information